The Company has decided to move the annual general meeting to 27 May 2024. The new notice is stated below, which also replaces the previously published notice. The Company has also decided to move the publication of the Company’s interim report for Q1 to 17 May 2024.
The shareholders in Prolight Diagnostics AB (publ), corp. reg. no. 556570-9499, (the ”Company”) are hereby notified of the annual general meeting to be held on Monday 27 May 2024 at 1 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden.
Notification of attendance
Shareholders who wish to participate in the annual general meeting must:
– Be recorded in the share register maintained by Euroclear Sweden AB on Friday 17 May 2024; and
– Give notice to the Company of their intention to attend the meeting no later than on Tuesday 21 May 2024.
Notification of attendance is to be sent by post to Prolight Diagnostics AB (publ), c/o Advokatfirman Lindahl KB, Studentgatan 6, 211 38 Malmö, Sweden (mark the letter “Annual general meeting”) or by e-mail to prolightdiagnostics@lindahl.se. When giving notice, shareholders should state their name, personal ID/corporate registration number (or equivalent), address, telephone number, the names of any advisers (maximum two) and, when applicable, the name of a proxy or legal representative.
Nominee-registered shares
Shareholders who have registered their shares in the name of a nominee must, in addition to the notification, request registration of the shares in their own name in the register maintained by Euroclear Sweden AB. Registration of shareholders should be completed no later than on 21 May 2024. Such registration may be temporary. The shareholder should notify the nominee well in advance of this date.
Proxies
Shareholders who intend to be represented by proxy must issue a dated power of attorney for the proxy. If the power of attorney is issued by a legal entity, a copy of the certificate of registration or its equivalent for the legal entity must also be presented. The period of validity of the power of attorney is permitted to be up to five years from the date of issue. To facilitate entry at the Meeting, copies of proxies, registration certificates and other authorisation documents should be enclosed with the notice of participation. The Company provides proxy forms on request and these are also available at the Company website, www.prolightdx.com.
Proposed agenda
1. Opening of the meeting and election of the chairman for the meeting
2. Establishment and approval of the voting list
3. Approval of the agenda
4. Election of one or two persons to verify the minutes
5. Determination as to whether the Meeting has been duly convened
6. Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group for the financial year 2023
7. Resolution regarding:
a) The adoption of the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet for the financial year 2023
b) The allocation of the Company’s result in accordance with the adopted balance sheet
c) Discharge from liability for members of the Board of Directors and the Managing Director
8. Determination on the number of Board members, deputy Board members, auditors and deputy auditors
9. Determination on the remuneration to the Board members and the auditor
10. Election of Board members, Chairman of the Board and of auditor
11. Resolution regarding authorisation for the Board of Directors to resolve on issues of new shares, warrants and/or convertible instruments
12. Resolution regarding amendment to incentive program resolved on by an extraordinary general meeting in 2022
13. Resolution regarding an incentive program in the form of employee stock options for employees, including a directed issue and transfer of warrants
14. Closing of the Meeting
Resolution proposal
The Nomination Committee has submitted proposals for items 1 and 8–10. The Nomination Committee has been appointed in accordance with the principles decided by the annual general meeting 2022 and comprises of (i) Christer Sjödoff, representing Cardeon AB, (ii) Paul Monaghan, representing his own shares and (iii) Jan Karlsson, representing MTT Capital AB. Chairman of the Nomination Committee has been Jan Karlsson.
Item 1 – Election of the chairman for the meeting
The Nomination Committee proposes Masoud Khayyami be elected as chairman for the meeting or, in his absence, the person appointed by the board.
Item 7 b) – The allocation of the Company’s profit in accordance with the adopted balance sheet
The Board of Directors proposes that no dividend shall be paid for the financial year 2023, i.e. that the net profit for the year be carried forward.
Item 8 – Determination on the number of Board members, deputy Board members, auditors and deputy auditors
The Nomination Committee proposes that the number of Board members elected by the annual general meeting be seven without deputies. Furthermore, the Committee proposes one auditor with no deputy.
Item 9 – Determination on the remuneration to the Board members and the auditor
The Nomination Committee proposes that Board fees shall be paid in the amount of SEK 240,000 (120,000) to each Board member, and in the amount of SEK 400,000 (200,000) to the Chairman of the Board. The fees include remuneration for any committee work. A board member employed by the Company or by a subsidiary shall not receive a fee.
The Nomination Committee also proposes that fees to the auditor are paid against approved invoices.
Item 10 – Election of Board members, Chairman of the Board and of auditor
The Nomination Committee proposes, until the end of the next annual general meeting, that Masoud Khayyami, Maria Holmlund, Ulf Bladin, Steve Ross, Aileen McGettrick and Tobias Volker be re-elected as Board members and that Kiarash Farr be elected as new Board member. It is proposed that Masoud Khayyami be re-elected as Chairman of the Board.
Kiarash Farr is a Master of Science in Engineering Physics from Royal Institute of Technology (KTH) Stockholm and Management from INSEAD, Fontainebleau France. Kiarash is currently Senior Vice President of Commercial Operations at Boule. Kiarash has previously been Senior Director, Commercial Operations of the EMEA region at Hycor Biomedical, Sales Director Key account management at Thermo Fisher Scientific Immuno Diagnostics Division, and Business Director Asia at IBA with various leadership positions in Germany, China and India.
The other proposed Board members are presented on the Company website, www.prolightdx.com.
The Nomination Committee proposes, in accordance with the Board of Directors’ recommendation, the re-election of the registered accounting firm Mazars AB until the end of the next annual general meeting. Mazars AB has notified that authorised public accountant Jesper Ahlkvist will serve as the auditor in charge.
Item 11 – Resolution regarding authorisation for the Board of Directors to resolve on issues of new shares, warrants and/or convertible instruments
The Board of Directors proposes it be authorised to, on one or several occasions during the period until the next annual general meeting, resolve to increase the Company’s share capital by issuing new shares, warrants and/or convertible instruments not exceeding 50 percent of the share capital of the Company at the time of the annual general meeting’s resolution on the authorisation. The Board of Directors shall be authorised to issue the new shares, warrants and/or convertible instruments with deviation from shareholders’ pre-emption rights and payment may, apart from payment in cash, be made in kind or by set-off or otherwise be subject to terms and conditions in accordance with Chapter 2, Section 5, second paragraph 1-3 and 5 of the Swedish Companies Act.
Any issues shall be conducted under market conditions. The Board of Directors shall determine the other conditions for issues in accordance with this authorisation and who shall have the right to subscribe for shares, warrants and/or convertible instruments. The purpose of the authorisation and the reasons for any deviation from the shareholders’ pre-emption rights and/or subscription being subject to payment in kind or by set-off or other terms and conditions as stated above, is that issues may be made for acquisitions of companies or businesses, as well as private placements to capitalise the Company.
The Managing Director or the person nominated by the Board of Directors, shall be authorised to make minor amendments to the annual general meeting’s resolution that may be required in connection with the registration of the resolution with the Swedish Companies Registration Office and with Euroclear Sweden AB.
A resolution in accordance with the proposal is valid only if supported by shareholders holding at least two-thirds of both the votes cast and the shares represented at the meeting.
Item 12 – Resolution regarding amendment to incentive program resolved on by an extra ordinary general meeting in 2022
The Board of Directors proposes that the annual general meeting resolve on a minor adjustment of the incentive program for employees in the Company’s wholly owned subsidiary Psyros Diagnostics Ltd that was implemented by the extraordinary general meeting on 4 August 2022.
The Board of Directors proposes that the maximum allocation of employee stock options per participant within the category “Management” be increased from 1,500,000 employee stock options to 2,000,000 employee stock options and that the maximum allocation of employee stock options per participant within the category “Other valuable employees” be increased from 200,000 employee stock options to 300,000 employee stock options. Otherwise, the incentive program shall continue on unchanged terms and conditions. The purpose of the adjustment is that it is deemed to make it easier for the Company to recruit and retain employees. For the sake of order, the main terms of the incentive program, including the proposed adjustment, as resolved at the extraordinary general meeting on 4 August 2022, are outlined below.
Background and motive
The Board of Directors deems it important and in the interest of all shareholders that the employees of the group have a long-term interest in a favourable trend in the Company’s share price.
Through an employee stock option-based incentive program for current and future employees in the Company’s wholly owned subsidiary Psyros Diagnostics Ltd, employees’ reward can be linked to the Company’s future performance and value development. Long-term value growth is thus rewarded, aligning the goals of shareholders and concerned employees. Stock-related incentive programs further create a common focus for concerned employees and thereby prioritise long-term actions. Additionally, such incentive programs are deemed to facilitate the Company in recruiting and retaining employees.
Considering the terms, allocation size, and other circumstances, the Board of Directors assesses that the proposed incentive program outlined below is reasonable and beneficial for the Company and its shareholders.
The detailed contents of the employee stock option program are outlined below.
A. The Board of Directors’ proposal for resolution regarding the implementation of an employee stock option program 2022/2029
The Board of Directors proposes that the annual general meeting resolve to implement an employee stock option program 2022/2029 according to the guidelines below (the “Employee Stock Option Program”):
1. The employee stock option program shall comprise of a maximum of 8,000,000 employee stock options.
2. Each employee stock option entitles the holder to acquire one (1) new share in the Company at an exercise price equal to the closing price of the Company’s share on the NGM Nordic SME on the trading day preceding the day the employee stock option is granted.
3. The exercise price and the number of shares each employee stock option entitles to may be subject to adjustment due to bonus issues, splits, preferential rights issues, and similar measures, whereby the adjustment terms in the complete terms of the warrant shall apply.
4. The Employee Stock Option Program shall include current and future employees of the Company’s wholly owned subsidiary Psyros Diagnostics Ltd (excluding those employees who are also board members of the Company), and the Board of Directors of the Company shall have the right to decide on the allocation of employee stock options in accordance with the following guidelines:
| Category | Number of participants in the category | Maximum allocation of employee stock options per participant |
| Management | 3 | 2,000,000 |
| Experts | 5 | 500,000 |
| Other valuable employees | 17 | 300,000 |
5. The Board of Directors may decide on the allocation of employee stock options until the end of 2024.
6. Allocated employee stock options shall vest over a period of four years from the allocation date, in accordance with the following:
a) 75 percent of the employee stock options shall be deemed vested three years from the allocation date, and
b) additional 6,25 percent of the employee stock options shall be deemed vested every three months thereafter; thus, after four years, all employee stock options will be vested.
7. Vesting of employee stock options is conditional upon the holder being employed within the Company group. Furthermore, vested employee stock options may only be exercised if the holder remains employed within the Company group, or within a short period after the termination of employment.
8. Employee stock options may not be transferred or pledged.
9. The employee stock options shall be allocated free of charge. The participant can exercise allocated and vested employee stock options after the end of the vesting period mentioned above, but no later than five years after the allocated date.
10. Participation in the Employee Stock Option Program is conditional upon both legal eligibility for such participation and, according to the Company’s assessment, can take place with reasonable administrative costs and financial efforts.
11. The employee stock options shall be governed by a separate agreement with the participant. The Board of Directors shall be responsible for the design and management of the Employee Stock Option Program within the framework of the main terms and guidelines specified above. The Board of Directors has the right, within the framework of the agreement with each participant, to make reasonable changes and adjustments to the terms of the employee stock options deemed appropriate or necessary due to local labour or tax laws or administrative conditions. This may include continuing the vesting of employee stock options in certain cases where it would not otherwise have occurred. The Board of Directors also has the right to accelerate vesting and the timing of the exercise of employee stock options in certain cases, such as in the event of a public takeover offer, certain changes in ownership in the company, liquidation, merger, and similar measures. Finally, the Board of Directors has the right to, in extraordinary circumstances, limit the scope of or terminate the Employee Stock Option Program, in whole or in part, prematurely.
Costs, dilution effects and effects on relevant key figures
As the Employee Stock Option Program is implemented in accordance with special tax rules under British law, the Company’s assessment is that no costs for social security contributions or similar will arise for the Company. Therefore, the costs will mainly consist of limited expenses for the implementation and administration of the program. The incentive program is not expected to incur any significant costs for the Company. Furthermore, the options have no market value as they are non-transferable.
The proposed incentive program comprises a total of up to 8,000,000 employee stock options that can be exercised for the subscription of a total of up to 8,000,000 shares, corresponding to a dilution effect of up to approximately 2.8 percent based on the number of shares and votes in the Company after the exercise of the employee stock options. The Company’s share capital may increase by up to 800,000 kronor, subject to the increase that may be caused by adjustments according to the terms of the warrants.
The dilution and costs associated with establishing and administering the incentive program are expected to have a marginal impact on the Company’s key figures.
Preparation of the proposal
The proposed amendment has been prepared by the Board of Directors after obtaining input from major shareholders and independent experts and has been discussed at board meetings in early 2024.
Majority requirement
A resolution in favour of the proposal requires the support of shareholders representing a minimum of nine tenths of the votes cast and nine tenths of the shares represented at the annual general meeting.
Outstanding and previous share-related incentive programs
The Company resolved at an extraordinary general meeting on 4 August 2022 to establish a number of incentive programs for board members and senior executives in the Company as well as employees in the Company’s subsidiary Psyros Diagnostics Ltd.
The program for board member Maria Holmlund comprises a total of 500,000 warrants, of which all warrants are outstanding and held by Maria Holmlund. Each warrant gives the holder the right to subscribe for one (1) new share in the Company during the period from 1 September 2025 to 30 November 2025 at a subscription price corresponding to SEK 1.
The program for the senior executives Ulf Bladin (managing director) and Tobias Volker (subsidiary executive) comprises a total of 2,000,000 warrants, of which all warrants are outstanding and held by the participants in the program. Each warrant gives the holder the right to subscribe for one (1) new share in the Company during the period from 1 September 2025 to 30 November 2025 at a subscription price corresponding to SEK 1.
The program for employees in the Company’s wholly owned subsidiary Psyros Diagnostics Ltd includes a maximum of 8,000,000 employee stock options, of which 5,370,000 are outstanding and held by participants in the incentive program. Each employee stock option entitles the holder to acquire one (1) new share in the Company at an exercise price corresponding to the closing price of the Company’s share on the NGM Nordic SME on the trading day preceding the day the employee stock option was allocated to the respective participant. Allocated employee stock options vest over a period of four years from the date of allocation and in accordance with the following: a) 75 percent of the employee stock options shall be considered vested three years from the date of allocation, and b) an additional 6.25 percent of the employee stock options shall be deemed vested every three months thereafter, i.e. after four years, all employee options will be vested.
Item 13 – Resolution regarding an incentive program in the form of employee stock options for employees, including a directed issue and transfer of warrants
The Board of Directors of Prolight Diagnostics AB (publ) corp. reg. no. 556570-9499 (the ”Company”) proposes that the annual general meeting resolve on a long-term incentive program for employees in the Company’s wholly owned subsidiary Psyros Diagnostics Ltd, by issuing employee stock options, including a directed issue of warrants.
Background and motive
The Board of Directors deems it important and in the interest of all shareholders that the employees of the group have a long-term interest in a favourable trend in the Company’s share price.
Through an employee stock option-based incentive program for current and future employees in the Company’s wholly owned subsidiary Psyros Diagnostics Ltd, employees’ reward can be linked to the Company’s future performance and value development. Long-term value growth is thus rewarded, aligning the goals of shareholders and concerned employees. Stock-related incentive programs further create a common focus for concerned employees and thereby prioritise long-term actions. Additionally, such incentive programs are deemed to facilitate the Company in recruiting and retaining employees.
Considering the terms, allocation size, and other circumstances, the Board of Directors assesses that the proposed incentive program outlined below is reasonable and beneficial for the Company and its shareholders.
The detailed contents of the employee stock option program are outlined below. To ensure the Company’s commitments under the employee stock option program, the Board of Directors also proposes that the annual general meeting resolve on a directed issue of warrants and approve the transfer of warrants in accordance with the details provided under Section B below.
A. The Board of Directors’ proposal for resolution regarding the implementation of an employee stock option program 2024/2031
The Board of Directors proposes that the annual general meeting resolve to implement an employee stock option program 2024/2031 according to the guidelines below (the “Employee Stock Option Program”):
1. The employee stock option program shall comprise of a maximum of 2,000,000 employee stock options.
2. Each employee stock option entitles the holder to acquire one (1) new share in the Company at an exercise price equal to the closing price of the Company’s share on the NGM Nordic SME on the trading day preceding the day the employee stock option is granted.
3. The exercise price and the number of shares each employee stock option entitles to may be subject to adjustment due to bonus issues, splits, preferential rights issues, and similar measures, whereby the adjustment terms in the complete terms of the warrant shall apply.
4. The Employee Stock Option Program shall include current and future employees of the Company’s wholly owned subsidiary Psyros Diagnostics Ltd (excluding those employees who are also board members of the Company), and the Board of Directors of the Company shall have the right to decide on the allocation of employee stock options in accordance with the following guidelines:
| Category | Number of participants in the category | Maximum allocation of employee stock options per participant |
| Management | 4 | 2,000,000 |
| Experts | 7 | 500,000 |
| Other valuable employees | 10 | 300,000 |
5. The Board of Directors may decide on the allocation of employee stock options until the end of 2026.
6. Allocated employee stock options shall vest over a period of four years from the allocation date, in accordance with the following:
a) 75 percent of the employee stock options shall be deemed vested three years from the allocation date, and
b) additional 6,25 percent of the employee stock options shall be deemed vested every three months thereafter; thus, after four years, all employee stock options will be vested.
7. Vesting of employee stock options is conditional upon the holder being employed within the Company group. Furthermore, vested employee stock options may only be exercised if the holder remains employed within the Company group, or within a short period after the termination of employment.
8. Employee stock options may not be transferred or pledged.
9. The employee stock options shall be allocated free of charge. The participant can exercise allocated and vested employee stock options after the end of the vesting period mentioned above, but no later than five years after the allocated date.
10. Participation in the Employee Stock Option Program is conditional upon both legal eligibility for such participation and, according to the Company’s assessment, can take place with reasonable administrative costs and financial efforts.
11. The employee stock options shall be governed by a separate agreement with the participant. The Board of Directors shall be responsible for the design and management of the Employee Stock Option Program within the framework of the main terms and guidelines specified above. The Board of Directors has the right, within the framework of the agreement with each participant, to make reasonable changes and adjustments to the terms of the employee stock options deemed appropriate or necessary due to local labour or tax laws or administrative conditions. This may include continuing the vesting of employee stock options in certain cases where it would not otherwise have occurred. The Board of Directors also has the right to accelerate vesting and the timing of the exercise of employee stock options in certain cases, such as in the event of a public takeover offer, certain changes in ownership in the company, liquidation, merger, and similar measures. Finally, the Board of Directors has the right to, in extraordinary circumstances, limit the scope of or terminate the Employee Stock Option Program, in whole or in part, prematurely.
B. The Boards of Directors’ proposal for a resolution on the issue of warrants with deviation from the shareholders’ pre-emptive rights.
To ensure the Company’s delivery of shares under the Employee Stock Option Program, the Board of Directors proposes that the annual general meeting resolve on a directed issue of a maximum of 2,000,000 warrants and approve the transfer of warrants as follows:
1. The right to subscribe for new warrants shall, with deviation from the shareholders’ pre-emptive rights, belong to the Company.
2. The reason for deviating from the shareholders’ pre-emptive rights is stated under the heading “Background and motive” above and constitutes part of the implementation of the Employee Stock Option Program.
3. Subscription for the warrants shall be made by subscribing to a subscription list no later than within one week from the resolution on the issue. The Board of Directors shall have the right to extend the subscription period.
4. All warrants are to be issued free of any consideration.
5. The Company shall have the right to transfer warrants to participants in the Employee Stock Option Program without consideration in connection with the exercise of employee stock options in accordance with the terms under A or otherwise dispose of the warrants to ensure the Company’s commitments in relation to the Employee Stock Option Program, such transfer being approved by the annual general meeting through the resolution. The Board of Directors shall not have the right to dispose of the warrants for any purpose other than to ensure the Company’s commitments in relation to the Employee Stock Option Program.
6. If all warrants are exercised for the subscription of shares, the Company’s registered share capital will increase by up to SEK 200,000.
7. Each warrant shall entitle the holder to subscribe for one new share in the Company at a subscription price equivalent to SEK 0,1, which corresponds to the quotient value of the Company’s shares. The subscription price may not be lower than the quotient value of the Company’s shares.
8. The part of the subscription price for a share subscribed for based on a warrant that exceeds the quota value of the previous shares shall be included under the free share premium reserve.
9. Subscription of shares upon exercise of the warrants shall be made in accordance with the terms and conditions for the warrants during the period from the day of registration of the warrants with the Swedish Companies Registration Office and until 31 March 2032.
10. A share that has been issued pursuant to exercise of a warrant entitles to dividends for the first time on the first record date for dividend that take place after the subscription of new shares has been registered with the Swedish Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB.
11. The managing director, or the person appointed by the Board of Directors, shall have the right to make minor adjustments as may be necessary in connection with the registration of the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.
Costs, dilution effects and effects on relevant key figures
As the Employee Stock Option Program is implemented in accordance with special tax rules under British law, the Company’s assessment is that no costs for social security contributions or similar will arise for the Company. Therefore, the costs will mainly consist of limited expenses for the implementation and administration of the program. The incentive program is not expected to incur any significant costs for the Company. Furthermore, the options have no market value as they are non-transferable.
The proposed incentive program comprises a total of up to 2,000,000 employee stock options that can be exercised for the subscription of a total of up to 2,000,000 shares, corresponding to a dilution effect of up to approximately 0.4 percent based on the number of shares and votes in the Company after the exercise of the employee stock options. The Company’s share capital may increase by up to 200,000 kronor, subject to the increase that may be caused by adjustments according to the terms of the warrants.
The proposed incentive program, together with other outstanding incentive programs comprises a total of up to 12,500,000 employee stock options/warrants that can be exercised for the subscription of a total of up to 12,500,000 shares, corresponding to a dilution effect of up to approximately 2.4 percent based on the number of shares and votes in the Company after the exercise of the warrants. The Company’s share capital may increase by up to 1,250,000 kronor, subject to the increase that may be caused by adjustments according to the terms of the warrants.
The dilution and costs associated with establishing and administering the incentive program are expected to have a marginal impact on the Company’s key figures.
Preparation of the proposal
The proposal has been prepared by the Board of Directors after obtaining input from major shareholders and independent experts and has been discussed at board meetings in early 2024.
Majority requirement
A resolution in favour of the proposal requires the support of shareholders representing a minimum of nine tenths of the votes cast and nine tenths of the shares represented at the annual general meeting.
Outstanding and previous share-related incentive programs
The Company resolved at an extraordinary general meeting on 4 August 2022 to establish a number of incentive programs for board members and senior executives in the Company as well as employees in the Company’s subsidiary Psyros Diagnostics Ltd.
The program for board member Maria Holmlund comprises a total of 500,000 warrants, of which all warrants are outstanding and held by Maria Holmlund. Each warrant gives the holder the right to subscribe for one (1) new share in the Company during the period from 1 September 2025 to 30 November 2025 at a subscription price corresponding to SEK 1.
The program for the senior executives Ulf Bladin (managing director) and Tobias Volker (subsidiary executive) comprises a total of 2,000,000 warrants, of which all warrants are outstanding and held by the participants in the program. Each warrant gives the holder the right to subscribe for one (1) new share in the Company during the period from 1 September 2025 to 30 November 2025 at a subscription price corresponding to SEK 1.
The program for employees in the Company’s wholly owned subsidiary Psyros Diagnostics Ltd includes a maximum of 8,000,000 employee stock options, of which 5,370,000 are outstanding and held by participants in the incentive program. Each employee stock option entitles the holder to acquire one (1) new share in the Company at an exercise price corresponding to the closing price of the Company’s share on the NGM Nordic SME on the trading day preceding the day the employee stock option was allocated to the respective participant. Allocated employee stock options vest over a period of four years from the date of allocation and in accordance with the following: a) 75 percent of the employee stock options shall be considered vested three years from the date of allocation, and b) an additional 6.25 percent of the employee stock options shall be deemed vested every three months thereafter, i.e. after four years, all employee options will be vested.
Information concerning the annual general meeting
The Board of Directors and the Managing Director shall, upon request by any shareholder and where the Board of Directors believes that it can be done without significant harm to the Company, provide information concerning circumstances which may affect the assessment of an item on the agenda or the Company’s financial condition. The duty to provide information also applies to such circumstances regarding the Company’s subsidiaries, its relationship to other Group Companies and to the group accounts.
Available documentation
The financial statements and auditor’s report, as well as other documents pursuant to the Swedish Companies Act, will be available at the Company’s office on Gasverksgatan 3 A, 222 29 Lund, Sweden and on the Company website, www.prolightdx.com, not later than three weeks before the annual general meeting. The documents will also be sent free of charge to shareholders who have requested this and provided their postal address. The documents will also be available at the meeting.
Processing of personal data
For information regarding the processing of your personal data in connection with the annual general meeting, please refer to the privacy policy available on Euroclear Sweden AB’s website: https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.
__________________
Lund in April 2024
Prolight Diagnostics AB (publ)
Board of Directors
